CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 160 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $481,105 | -42.7% | 17,482 | -29.3% | 0.22% | -41.9% |
| Q2 2023 | $839,496 | -5.7% | 24,742 | 0.0% | 0.38% | -47.0% |
| Q1 2023 | $890,217 | -19.3% | 24,742 | 0.0% | 0.72% | +10.7% |
| Q4 2022 | $1,102,751 | +54.2% | 24,742 | -2.7% | 0.66% | +60.5% |
| Q3 2022 | $715,000 | +18.4% | 25,426 | +13.4% | 0.41% | +11.8% |
| Q2 2022 | $604,000 | -31.1% | 22,412 | -12.9% | 0.36% | -34.6% |
| Q1 2022 | $877,000 | -24.0% | 25,738 | -13.8% | 0.56% | -39.3% |
| Q4 2021 | $1,154,000 | -24.9% | 29,856 | +4.9% | 0.92% | -9.6% |
| Q3 2021 | $1,537,000 | +35.7% | 28,466 | -16.0% | 1.02% | +26.5% |
| Q2 2021 | $1,133,000 | +67.1% | 33,893 | +2.9% | 0.80% | +59.5% |
| Q1 2021 | $678,000 | -22.3% | 32,940 | -33.9% | 0.50% | -9.7% |
| Q4 2020 | $873,000 | +31.3% | 49,855 | +11.2% | 0.56% | +15.1% |
| Q3 2020 | $665,000 | – | 44,829 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
| Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
| TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
| ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
| 5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
| COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
| RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
| Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
| Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
| Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |